Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation

Estelle Louiset (1, 2, 3, 4, 5)

1 UNIROUEN - Université de Rouen Normandie
2 DC2N - Différenciation et communication neuronale et neuroendocrine
3 DC2N - Différenciation et communication neuronale et neuroendocrine
4 Neuroendocrinologie cellulaire et moléculaire
5 INSERM - Institut National de la Santé et de la Recherche Médicale

Medullary thyroid carcinomas (MTCs) complicated by ectopic Cushing's syndrome (CS) have a poor prognosis, partially due to the difficulty in controlling hypercortisolism by adrenal blocking drugs. Recent reports (including the initial follow-up of this patient) have suggested that tyrosine kinase inhibitors (TKIs) may be a therapeutic option due to an anti-secretory action on ACTH. However, there is a lack of long-term follow-up studies.

Keywords: Cushing's syndrome; RET; hypercortisolism; medullary thyroid carcinoma; vandetanib

Domains: Life Sciences [q-bio]; Human health and pathology; Endocrinology and metabolism; Life Sciences [q-bio]; Cellular Biology; Cell Behavior [q-bio.CB]; Life Sciences [q-bio]; Human health and pathology; Tissues and Organs [q-bio.TO]

Estelle Louiset. Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation. Thyroid, 2017, 27 (4), pp.587-590. ⟨10.1089/thy.2016.0334⟩. ⟨hal-01945860⟩